Several of the heterogeneous clinical manifestations of systemic lupus erythematosus have been associated with specific autoantibodies. Associations between HLA class II antigens and autoantibodies to the ribonucleoproteins Ro(SSA) and La(SSB) have been reported in these patients. Because HLA class II molecules present antigen to T cell receptors (TCRs), we have searched for a TCR gene associated with the production of anti-Ro(SSA) antibodies. A pair of restriction fragment length polymorphisms (RFLPs), one of which hybridizes to the TCR constant region C beta 1 and the other to the C beta 2 gene, has been identified, suggesting these may be genotypic markers for an extended region of the TCR beta locus. This RFLP pair occurs in 76% of patients with Ro(SSA) precipitins, 84% of anti-Ro(SSA)-positive patients lacking La(SSB) precipitins, but only 41% of the patients lacking both precipitins (P = 0.0004). This disproportionate occurrence in a subset of lupus patients indicates that these RFLPs are not disease susceptibility markers, but rather are important markers for TCR genes whose products are involved in the production of antiRo(SSA) antibodies. The majority of patients who have these RFLPs and HLA class II antigens previously associated with the anti-Ro(SSA) response make this antibody, suggesting that interactions between products of these loci occur in response to Ro(SSA).
Introduction
Systemic lupus erythematosus (SLE)' is a rheumatic disease of unknown etiology and complex pathogenesis. Its study is complicated by diverse clinical manifestations and heterogeneous laboratory findings. Abundant evidence has shown the importance of genetic contributions to the development of lupus. A several hundredfold increase in the incidence of the disease in relatives of patients compared with the general pop-TCRj3 locus; RFLP, restriction fragment length polymorphism; SLE, systemic lupus erythematosus; TCR, T cell receptor; V,6, variable region gene of the TCRB locus. ulation exists (1, 2) , and a high concordance in monozygotic vs. dizygotic twins has been reported (3, 4) . Associations between the HLA class II antigens HLA-DR2, -DR3, and -DR7 with the disease exist (5) (6) (7) (8) . Because of linkage disequilibrium between these loci and others in the HLA region, it remains to be determined whether these or alleles at other linked loci are most closely associated with disease predisposition (8) (9) (10) (11) (12) (13) . Recent work indicates that not only the disease as a whole, but also the presence of particular lupus autoantibodies are associated with histocompatibility genes (14) (15) (16) (17) (18) .
Ro(SSA) is a ribonucleoprotein particle consisting of a polypeptide chain of -60 kD associated with one of four small (83-112 base) RNA molecules (19) (20) (21) (22) . This complex, whose function is currently unknown, is present in all mammalian cells that have been studied. Anti-Ro(SSA) autoantibodies are typically found in 30-50% of lupus patients and in up to 96% of patients with primary Sjogren's syndrome (21, 23) . In lupus patients these antibodies are associated with lymphopenia, photosensitive dermatitis, and pulmonary disease (15, 17, (24) (25) (26) (27) . Antibodies against Ro(SSA) are enriched in acid eluates of nephritic kidneys of lupus patients when compared with their serum antibody levels, suggesting their role in lupus nephritis (28) . Exogenous anti-Ro(SSA) antibodies deposit in human skin grafts on severe combined immune deficiency mice in patterns similar to those seen in skin lesions of subacute cutaneous lupus patients (29) . The close association of maternal anti-Ro(SSA) with neonatal dermatitis and complete congenital heart block further suggests a pathogenic role for these antibodies (30) (31) (32) .
Patients with La(SSB) precipitins constitute a subset of those with Ro(SSA) precipitins. This patient subset differs in the frequencies of the HLA-DR2 and -DR3 antigens when compared with those having only anti-Ro(SSA) precipitins (1 1, 15) . In lupus patients the mutual occurrence of both antibodies is associated with a low frequency ofrenal disease when compared with patients with only anti-Ro(SSA) antibodies (17, 24) , and a high prevalence of photosensitivity, discoid rash, and sicca symptoms (23, 24, 33, 34) . In the absence of cytotoxic chemotherapy, the presence ofboth ofthese antibodies is stable irrespective of disease activity (24) . These findings suggest that genetic and clinical differences exist between the anti-Ro(SSA)-positive patients with and without the antiLa(SSB) autoantibody, and patients lacking the anti-Ro(SSA) antibodies.
Anti-Ro(SSA) autoantibodies in lupus patients have been associated with HLA class II antigens (14-16, 18, 35, 36) . In models of T cell activation, antigen is presented by MHC proteins to the T cell receptor (TCR). However, no investigations have shown differences between TCR genes of lupus patients and healthy controls (37) (38) (39) . These studies have considered lupus as a single disease entity without consideration of the heterogeneous antibody profiles or HLA class II differences of these patients, and therefore do not mean that important rela-tionships with TCRs do not exist. In this study we have investigated the role of TCRs in the production of anti-Ro(SSA) antibodies. The immunologically defined subgroup of patients with this autoantibody is more homogeneous genetically and clinically than the group of lupus patients as a whole. The combination of a new restriction fragment length polymorphism (RFLP) with the previously described Bgl II TCR,3 RFLP permitted us to identify a genotypic marker that is strongly associated with anti-Ro(SSA) autoantibodies. Our data further suggested that a TCR gene product may interact with particular HLA class II antigens in the development or perpetuation of this autoimmune response. This is the first example of an association between a TCR gene and an immune response to a known autoantigen in humans. TBl (41) . This TCR Cft insert was isolated using a preparative 5% N,N'-bis-acrylylcystamine crosslinked polyacrylamide gel (Bio-Rad Laboratories, Richmond, CA) and DEAE-cellulose ion-exchange chromatography, and used as a probe in this study.
Patients and DNA protocols. A minimum of 30 ml of anticoagulated peripheral blood was collected from 70 female and 6 male patients diagnosed with SLE (42 (43), and prehybridized for 4 h at 65°C in 5X SSPE (0.75 M NaCl, 50 mM NaH2PO4/H20, 5 mM EDTA, pH 7.0), lOX Den- hardt's solution (0.2% BSA, 0.2% ficoll, 0.2% polyvinylpyrrolidone), 5% dextran sulfate, 0.1% SDS, 50 mM phosphate buffer, and 50 ug/ml of denatured salmon sperm DNA. The prehybridization solution was replaced with fresh solution and hybridization was performed overnight at 650C with the radiolabeled TCR C# probe (44, 45) . Membranes were washed at high stringency with 0.2x SSPE and 0.1% SDS at 650C. Sizes of RFLP bands were estimated by autoradiography (X-Omat AR film; Eastman Kodak Co., Rochester, NY) relative to the migration of Hind III-digested lambda bacteriophage DNA and Hae III-digested phiX-174 DNA (Bethesda Research Laboratories, Gaithersburg, MD).
Detection ofpatient autoantibodies. Patient sera were analyzed for the presence of anti-Ro(SSA) and anti-La(SSB) antibodies against bovine spleen extracts relative to reference sera by Ouchterlony immunodiffusion and counter immunoelectrophoresis (19, 24) .
Statistical analysis. Statistical analysis of RFLPs was carried out using Fisher's exact test with the Epistat software package for PC-based computer systems (T. Gustafson, Round Rock, TX). The chi-square test was used to test for homogeneity and genotypic differences between groups. Statistical levels of confidence are shown without adjustment for the number of comparisons made.
Results
In preliminary experiments DNA from 13 Because strong associations between HLA class II region markers and anti-Ro(SSA) antibodies have been described in lupus patients, we wished to determine if the markers for the TCR genes we identified might be useful in detecting associations between TCRB genes and the anti-Ro(SSA) response. An increase in the allelic frequency of the Bgl 11 9.8-kb (P = 0.05) as well as the Kpn I 1.75-kb (P = 0.05) RFLP was found in the 42 patients with the Ro(SSA) precipitin when compared with the 34 patients who lacked this precipitin (Table I) . Genotypi- (Table I ) also had the Kpn I 1.75-kb RFLP. Table II shows that the combination of these two RFLPs was present in 76% of the patients with Ro(SSA) precipitins. In contrast, it occurred in only 14 of 34 patients (41%) lacking this precipitin, resulting in a highly significant difference between these two patient groups (P = 0.002).
When all 76 lupus patients were considered as a single group, the frequency of these two Bgl II and Kpn I RFLPs did not differ from that found in 25 healthy subjects (Table III) . These results are consistent with those of others who have failed to find differences when comparing the Bgl II RFLPs between SLE patients and controls (37) (38) (39) . The joint occurrence of these two RFLPs does not, therefore, appear to be a risk factor for the disease. Rather, the RFLP combination is a marker for TCRj3 genes involved in the production of antiRo(SSA) antibodies in a subset of lupus patients (Table III) .
We have initiated experiments to determine whether the Bgl II 9.8-and Kpn I 1.75-kb markers preferentially occur on the same chromosome in lupus patients with the anti-Ro(SSA) precipitins. Ofthe Ro(SSA) precipitin-positive patients studied with both of these RFLPs, the linkage phase ofthese markers is in coupling (i.e., on the same chromosome) in 24 patients, and in repulsion (i.e., opposite chromosomes) in only 2 patients. However, these markers also occur on the same chromosome in 9 of the 15 Ro(SSA) precipitin-negative patients that we have studied. Fully informative pedigrees must be analyzed from additional patients before definitive results can be reached on this issue. However, these findings suggest that the mere presence ofthese RFLPs on the same chromosome is not sufficient for production of the anti-Ro(SSA) antibodies in lupus patients. Detection of a functional TCRf3 exon that codes for a TCR polypeptide recognizing the Ro(SSA) autoantigen will be required to determine whether these two RFLP markers are in linkage disequilibrium with such a gene. As discussed in the introduction, patients with the Ro(SSA) precipitin differ genetically at HLA loci and clinically from patients with both the Ro(SSA) and La(SSB) precipitins.
We have, therefore, divided the Ro(SSA)-positive patients into two groups based on the presence or absence of La(SSB) precipitins. A homogeneity chi-square test of the combined presence of the Bgl II 9.8-and Kpn I 1.75-kb RFLPs revealed significant differences between these two patient subsets (P < 0.05), suggesting on the basis ofthese RFLPs that patients in these groups should not be pooled. As expected in a cohort of this size (76 patients), the number of patients with both precipitins is small, and therefore conclusions regarding this particular subgroup should be considered tentative. Table IV shows that the proportion of patients with Ro(SSA) and La(SSB) precipitins who have both the Bgl II 9.8-and Kpn I 1.75-kb RFLPs is more similar to that found in patients lacking the Ro(SSA) precipitin (P = 0.33) than to patients with just the Ro(SSA) precipitin (P = 0.06). These two RFLPs occur in 84% of the patients with only the Ro(SSA) precipitin, thus reducing the probability eightfold (P = 0.0004) compared with that observed when Ro(SSA)-positive and -negative patients, irrespective of their La(SSB) precipitin status were analyzed above. Of the 32 Ro(SSA) precipitin-positive patients with both of these RFLPs, 26 of them lacked La(SSB) precipitins. Due to sample size, these findings suggest, but do not prove, that the group of Ro(SSA) precipitin-positive patients lacking La(SSB) precipitins are responsible for the differences between the Ro(SSA) precipitin-positive and -negative patients.
High titers of anti-Ro(SSA) antibodies have previously been described in HLA-DQ1/DQ2 heterozygous patients with primary Sjogren's syndrome and SLE (14, 17) . In this patient cohort, 11 of the 26 (42%) HLA typed patients with only the anti-Ro(SSA) precipitin are HLA-DQ1/DQ2 heterozygotes, compared with only 2 of 22 (9%) HLA-DQ typed antiRo(SSA)-negative patients (P = 0.01). If the TCR RFLPs are indeed markers for functional genes that recognize the Ro(SSA) antigen in conjunction with HLA class II molecules, one would expect to find an association between these TCR markers and these HLA-DQ antigens in Ro(SSA) precipitinpositive but not -negative patients. The Ro(SSA) precipitin was found in 20 of 24 patients (83%) with the HLA-DQ1 antigen who also had the TCRB RFLP markers, but in only 4 ofthe Ro(SSA) precipitin-negative patients with these markers (P = 0.004). The DQ2 serotype (P = 0.065) and DQ1/DQ2 heterozygosity (P = 0.013) were less strongly associated with these markers. The frequency of the joint occurrence of the HLA-DQ1 serotype and the TCR,# RFLPs in healthy individuals was similar to that in the Ro(SSA) precipitin-negative patients (P = 0.39). An association of this nature is not expected if the TCRB RFLPs are not markers for a functional TCR gene or regulatory element involved in TCR gene expression. These studies suggest the existence of a multigenic interaction between products of these loci in the generation of anti-Ro(SSA) antibodies.
Discussion
In this study we identified TCR# RFLPs that occur in a disproportionately high frequency in a subset of SLE patients with anti-Ro(SSA) antibodies. The majority of these patients lack anti-La(SSB) antibodies. Since no differences were found with respect to these RFLPs between patients when considered as a single group and healthy subjects, these RFLPs appear to be markers for the production of specific autoantibodies in lupus rather than risk factors for the disease. In studies by others the presence of Ro(SSA) and La(SSB) precipitins has been associated with clinical and genetic differences among lupus patients (1 1, 15, 17, [24] [25] [26] . Given findings of the pathophysiologic significance of anti-Ro(SSA) antibodies in lupus, these results suggest a role for TCR genes in the disease process.
Five patients who make only anti-Ro antibodies lack the Bgl II 9.8-and Kpn I 1.75-kb RFLPs. This finding and the observation that this RFLP combination is present in nearly half of all participants without detectable levels of antiRo(SSA) antibodies suggest that the RFLP markers themselves are neither necessary nor sufficient for the anti-Ro(SSA) response. This is not surprising considering that the nucleotide sequence differences of either of these polymorphic sites do not occur in coding regions, and therefore do not alter the amino acid sequence of TCR# polypeptides. We (15, 17) , DQ1/DQ2 heterozygosity has been most strongly associated with anti-Ro(SSA) antibodies. Together with data presented here, these findings allow us to expand upon a previous model suggesting a requirement for gene complementation between HLA-DQl (or DR2) and HLA-DQ2 (DR3) associated polypeptides for the presentation of the Ro(SSA) antigen in lupus and Sjogren's syndrome patients (14, 15, 17) (64) . The data presented here provide the first direct evidence for a specific, non-MHC gene involved in the regulation ofanti-Ro(SSA) autoantibodies. These data are the first to show an association between a TCR gene and a known human autoantigen, and are consistent with a model proposing that genes at multiple immune response loci determine the presence of particular antibodies in lupus patients, which in turn lead to the differential manifestations of this disease ( 17, 65) .
